Facility-level covariates (ICU density, antibiotic stewardship protocol) are the strongest predictors of HGT risk, explaining GBM outperformance over sequence-only LSTM
Adversarial Debate Score
27% survival rate under critique
Expert panel critique
Independent views, each critiquing the hypothesis on its own — the score rewards genuine disagreement and discounts consensus.
Supporting Research Papers
- A novel approach to antimicrobial resistance: Machine learning predictions for carbapenem-resistant Klebsiella in intensive care units
This study was conducted at Kocaeli University Hospital in Turkey and aimed to predict carbapenem-resistant Klebsiella pneumoniae infection in intensive care units using the Extreme Gradient Boosting ...
- Benchmarking Machine Learning Architectures for Antimicrobial Stewardship in Pediatric ICUs
Antimicrobial stewardship (AMS) is critical in pediatric intensive care units (PICUs), where diagnostic uncertainty often drives broad-spectrum antibiotic use, increasing antimicrobial resistance and ...
- Machine learning-based prediction of antimicrobial resistance and identification of AMR-related SNPs in Mycobacterium tuberculosis
Mycobacterium tuberculosis (MTB) is a human-specific pathogen that primarily infects humans, causing tuberculosis (TB). Antimicrobial resistance (AMR) in MTB presents a formidable challenge to global ...
- Forecasting Bacterial Antimicrobial Resistance Trends Using Machine Learning on WHO GLASS Surveillance Data: A Retrieval-Augmented Generation Approach for Policy Decision Support
Background: Antimicrobial resistance (AMR) is a global health threat. While the WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) provides standardized data, population-level mac...
- Differentiable latent structure discovery for interpretable forecasting in clinical time series
Background: Timely, uncertainty-aware forecasting from irregular electronic health records (EHR) can support critical-care decisions, yet most approaches either impute to a grid or sacrifice interpret...
Formal Verification
Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.
This discovery has a Claude-generated validation package with a full experimental design.
Precise Hypothesis
In a held-out, prospectively or retrospectively sampled cohort of hospital facilities and bacterial isolates, a gradient boosted machine (GBM) trained on facility-level covariates alone (ICU bed density, antibiotic stewardship protocol adherence score, hand-hygiene compliance rate, isolation-room capacity, patient turnover rate) will predict horizontal gene transfer (HGT)-mediated resistance acquisition (defined as acquisition of a mobile resistance element, e.g., plasmid-borne blaKPC, mcr-1, or vanA, confirmed by long-read sequencing/plasmid reconstruction) with AUROC ≥ the AUROC of a sequence-only LSTM trained on raw genomic/k-mer data from the same isolates, and this facility-covariate GBM will explain ≥60% of the variance explained by the best combined (genomic+facility) model, as measured by SHAP-based variance decomposition or nested model R² comparison.
- If the sequence-only LSTM (or an updated genomic model, e.g., a transformer on full assemblies/plasmid-typed contigs) achieves AUROC statistically indistinguishable from or greater than the GBM (95% CI overlap, DeLong test p>0.05) across ≥2 independent multi-site cohorts.
- If SHAP/permutation-importance decomposition shows genomic features (e.g., presence of known conjugative plasmid replicons, IS-element density) contribute ≥40% of explained variance once properly featurized (current LSTM may be an under-powered genomic encoder, which would falsify the mechanistic claim even if outperforming empirically).
- If facility covariates lose predictive power when tested out-of-distribution (new hospital systems, different countries/regulatory environments) — i.e., the effect is a hospital-specific confounder rather than a generalizable causal driver.
- If the association is fully attributable to outbreak clustering (facility covariates merely proxy for "this hospital had an outbreak this month") rather than modifiable stewardship/ICU practices, as revealed by time-lagged causal analysis (Granger-style test) showing no lead-lag relationship between stewardship changes and subsequent HGT rate changes.
Spine & Adversarial ReadReady for validation
“This hypothesis tests whether facility-level hospital covariates (ICU density, antibiotic stewardship adherence) predict horizontal gene transfer-mediated antibiotic resistance acquisition at least as well as sequence-only genomic models, when both are evaluated with facility-level (not isolate-level) train/test splitting to prevent leakage.”
- highThe reported GBM-over-LSTM outperformance is likely an artifact of comparing a strong tabular model against a weak, naively-featurized sequence model (raw k-mer LSTM) rather than a genuinely superior facility-covariate signal — modern genomic foundation models or properly engineered mobile-element features would likely close or reverse the gap.Protocol explicitly requires a stronger genomic baseline (foundation-model embeddings, e.g., Nucleotide Transformer) as a sensitivity analysis (Methodology step 10); this is not yet run and remains the single largest threat to the claim's validity — flagged as an open gap pending Phase 1 results.
- highWhy GBM and LSTM specifically, and why these particular facility covariates (ICU density, stewardship score) rather than other plausible confounders (regional antibiotic resistance prevalence, patient comorbidity burden, referral patterns)? The methodology choice is not justified against alternative model classes (e.g., causal forests, hierarchical Bayesian models) or a broader covariate set, raising the risk that the result is an artifact of an underspecified feature set rather than a genuine causal finding.This EVP does not yet provide a pre-specified rationale for excluding regional resistance prevalence and comorbidity data as covariates, nor does it justify GBM/LSTM as the canonical comparator pair beyond their use in the original discovery. A required amendment before execution: add a covariate-adequacy sensitivity analysis (e.g., adding regional AMR prevalence as a control variable) and justify model class choice against at least one causal-inference alternative (e.g., doubly-robust estimation) to rule out confounding-driven predictive success being mistaken for actionable causal signal.
- mediumFacility-level splitting with only 15-30 facilities will likely be underpowered to detect an AUROC difference of 0.05 with adequate confidence, meaning the study may return an inconclusive result that neither confirms nor disproves the hypothesis, wasting the full validation budget.Addressed partially via the Day 60 abort checkpoint and recommendation to switch to a Bayesian hierarchical model for small-N facility inference; however, no formal power calculation is provided in this EVP and should be computed before Day 0 committment of the full $260K budget.
Experimental Protocol
Minimum viable test (MVT): retrospective case-control design using ≥3 independent hospital systems (target n≥15 facilities, ≥1,500 bacterial isolates with paired WGS and facility metadata) with known HGT-resistance outcomes. Train GBM (facility covariates only), LSTM (k-mer/sequence only), and combined GBM+LSTM ensemble on 70% of facilities (site-stratified split to avoid leakage), validate on held-out 30% of facilities never seen in training (facility-level, not isolate-level, cross-validation is mandatory to avoid inflated genomic-model performance from site-specific strain clustering).
- Genomic: WGS of bacterial isolates with confirmed plasmid/mobile-element content — e.g., NCBI Pathogen Detection database, PATRIC/BV-BRC, CARD (Comprehensive Antibiotic Resistance Database), and any accessible hospital genomic surveillance datasets (e.g., NIH/CDC AR Isolate Bank, ESGEM/EUCAST surveillance sets).
- Facility metadata: CDC NHSN (National Healthcare Safety Network) facility-level stewardship and infection-control metrics, CMS Hospital Compare ICU bed/staffing data, or equivalent hospital-reported stewardship program self-assessment (CDC Core Elements checklist scores).
- Linkage requirement: isolate-to-facility-to-date linkage sufficient to timestamp HGT events against stewardship protocol changes — likely requires new data-sharing agreements (this is the single largest feasibility risk).
- Compute environment: standard ML stack (scikit-learn/XGBoost/LightGBM for GBM; PyTorch for LSTM baseline), SHAP library for variance decomposition, no specialized hardware required.
- Optional replication corpus: publicly available multi-site AMR genomic-epi datasets (e.g., the Enterobacteriaceae carbapenemase surveillance consortium data, if accessible) to test generalization.
- Facility-covariate GBM AUROC ≥ genomic LSTM AUROC with non-overlapping or GBM-favoring 95% CI in ≥2/3 independent cohorts (DeLong p<0.05).
- SHAP variance decomposition attributes ≥50% of combined-model explained variance to facility-covariate block.
- Effect replicates in external validation cohort with AUROC delta within ±0.05 of primary cohort (no major generalization collapse).
- Causal/temporal check shows directionally consistent (stewardship improvement → reduced HGT incidence) association with p<0.05 in difference-in-differences analysis for ≥1 facility with a documented protocol change.
- GBM AUROC significantly lower than LSTM/foundation-model genomic baseline in ≥2/3 cohorts.
- SHAP decomposition shows genomic features dominate (≥60% of variance) once a strong genomic encoder (foundation model) is substituted for the naive LSTM.
- Facility-covariate effect fails to replicate out-of-site (AUROC collapse >0.10 on external cohort) — indicates confounding/overfitting to site-specific outbreak clusters rather than a generalizable stewardship effect.
- No temporal/causal signal detected — facility covariates behave as static confounders rather than modifiable predictors, undermining the "actionable intervention" framing central to the impact claim.
120
GPU hours
150d
Time to result
$45,000
Min cost
$260,000
Full cost
ROI Projection
Moderate-to-high: enables a facility-risk-scoring SaaS product for hospital infection control teams (competitive with existing IPC dashboards from Epic/Cerner-adjacent vendors, BD Insights, Infection Control+); potential licensing to CDC NHSN or state health departments as a low-cost early-warning module; reduces reliance on expensive sequencing infrastructure, appealing to resource-limited health systems and LMIC hospital networks where genomic surveillance is currently infeasible cost-wise.
🔓 If proven, this unlocks
Proving this hypothesis is a prerequisite for the following downstream discoveries and applications:
- 1hospital-stewardship-intervention-RCT
- 2AMR-surveillance-resource-reallocation-policy
- 3facility-risk-scoring-tool-for-HGT-outbreak-early-warning
Implementation Sketch
# Phase 0: Cohort assembly & linkage facilities = link_isolates_to_facility_metadata(WGS_db, NHSN_db, CMS_db) labels = detect_HGT_events(facilities.isolates, tool=[PlasmidFinder, MobileElementFinder]) # Phase 1: Feature extraction X_facility = extract_covariates(facilities, cols=[icu_density, stewardship_score, hand_hygiene_pct, dot_per_1000pd]) X_genomic_lstm = kmer_embed(facilities.isolates.assemblies, k=8) X_genomic_foundation = nucleotide_transformer_embed(facilities.isolates.assemblies) # stronger baseline # Phase 2: Facility-level split (NOT isolate-level) train_fac, test_fac = split_by_facility(facilities, ratio=0.7, stratify='region') # Phase 3: Model training gbm = LightGBM().fit(X_facility[train_fac], labels[train_fac]) lstm = train_lstm(X_genomic_lstm[train_fac], labels[train_fac]) lstm_strong = train_classifier(X_genomic_foundation[train_fac], labels[train_fac]) ensemble = stack([gbm, lstm_strong]).fit(train_fac) # Phase 4: Evaluation for model in [gbm, lstm, lstm_strong, ensemble]: auroc, ci = bootstrap_auroc(model, test_fac, resample_unit='facility', n=1000) report(model.name, auroc, ci) # Phase 5: Variance decomposition shap_values = shap.TreeExplainer(ensemble).shap_values(test_fac) variance_share = decompose_by_feature_block(shap_values, blocks=['facility','genomic']) # Phase 6: Causal/temporal check did_result = difference_in_differences(facilities_with_protocol_change, outcome='HGT_incidence', lag_window=[30,90,180]) # Phase 7: External validation (frozen models, no retraining) external_auroc = evaluate_frozen(gbm, lstm_strong, ensemble, external_cohort)
- Day 30: if fewer than 3 facilities can be secured with both linked genomic + stewardship metadata at sufficient sample size (≥100 isolates/facility), abort or descope to single-cohort exploratory study.
- Day 60: if facility-level train/test split reduces effective sample size below statistical power threshold (power <0.7 for detecting AUROC difference of 0.05), reassess design (e.g., Bayesian hierarchical model instead of frequentist split).
- Day 90: interim analysis — if GBM vs. LSTM AUROC difference is not directionally consistent with the hypothesis on the first cohort, halt further cohort acquisition and pivot to failure-mode diagnosis (check foundation-model baseline first) before spending on cohorts 2–3.
- Day 120: if SHAP variance decomposition contradicts the AUROC finding (i.e., GBM wins on AUROC but genomic features dominate SHAP variance), treat as a methodological red flag requiring resolution before any external communication of results.